New drug combo aims to tackle hairy cell leukemia
NCT ID NCT06965114
First seen Nov 01, 2025 · Last updated Jun 22, 2026 · Updated 31 times
Summary
This study tests a combination of two drugs, tovorafenib and rituximab, in people with hairy cell leukemia that has returned or not responded to treatment, and also compares it to standard therapy for newly diagnosed patients. Tovorafenib blocks a protein that helps cancer grow, while rituximab helps the immune system attack cancer cells. The trial will check safety and how well the combination works in up to 84 participants.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HAIRY CELL LEUKEMIA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
NCI - Center for Cancer Research
RECRUITINGBethesda, Maryland, 20892, United States
Contact
Contact Phone: •••-•••-••••
-
Ohio State University Comprehensive Cancer Center
RECRUITINGColumbus, Ohio, 43210, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
University of Pittsburgh Cancer Institute (UPCI)
RECRUITINGPittsburgh, Pennsylvania, 15232, United States
Contact
Contact Phone: •••-•••-••••
-
University of Virginia Cancer Center
RECRUITINGCharlottesville, Virginia, 22908, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
tovorafenib and rituximab
What this could lead to
If successful, this could offer a new targeted treatment option for hairy cell leukemia, potentially improving remission rates and reducing relapse.
What could go wrong
This is an early-phase trial with a small number of participants (84). The combination may cause side effects or not prove more effective than current standard therapy.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.